Both Seaport and Hemab are hoping to bring in around $180 million each from their public listings this week, in the latest sign that biotech IPOs are regaining their momentum.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Both Seaport and Hemab are hoping to bring in around $180 million each from their public listings this week, in the latest sign that biotech IPOs are regaining their momentum.